Drug updated on 4/17/2024
| Dosage Form | Capsule (oral; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg); Chewable tablet (oral; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg) |
| Drug Class | Central nervous system stimulants |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
- Indicated for the treatment of moderate to severe binge eating disorder (BED) in adults.
Summary
- Lisdexamfetamine dimesylate (Vyvanse) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older, as well as moderate to severe binge eating disorder (BED) in adults. It has been found effective in reducing symptoms associated with both conditions.
- The information was derived from three systematic reviews/meta-analyses that focused on the effectiveness and safety of Vyvanse compared to other drugs used for treating ADHD and BED across various populations.
- In terms of its use for BED, Vyvanse is currently the only drug approved by the FDA specifically for this condition. Studies have shown consistent evidence that it effectively reduces symptoms and body weight among patients suffering from BED.
- When comparing different pharmacotherapies including Vyvanse, methylphenidate, atomoxetine, guanfacine, and others used to treat adult ADHD; all showed improvement over placebo but specific differences between medications were minimal due to low certainty evidence resulting from high or unclear risk bias present in most studies.
- For adult ADHD treatment, Vyvanse demonstrated a high effect size indicating significant potential. Compared with placebo, it had one of the largest effect sizes, suggesting more effectiveness than mixed amphetamine salts (MASs), methylphenidate (MPH), and modafinil (MDF).
- Regarding safety considerations; participants who received any ADHD pharmacotherapy, including Vyvanse, withdrew at higher rates due to adverse events when compared against those receiving placebos. However, serious adverse events or risks leading towards discontinuation did not significantly differ between those taking medication and those taking placebos, underscoring the need for further investigation into long-term effects.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vyvanse (lisdexamfetamine dimesylate) Prescribing Information. | 2023 | Takeda Pharmaceuticals America, Inc., Lexington |